InstalabLoading...
InstalabLoading...
Syphilis is quietly making a comeback, and the damage it causes when missed can reach your eyes, nerves, brain, and unborn children. The RPR (rapid plasma reagin) titer is the workhorse blood test used to tell whether the infection is currently active in your body and whether treatment has actually cleared it.
You get a number like 1:1, 1:8, or 1:32. Higher means more active disease. Falling after treatment means the therapy is working. This test does one job very well: it tracks how your immune system is responding to the syphilis bacterium over time.
RPR detects nontreponemal reagin antibodies, a class of antibodies your body makes in reaction to tissue damage caused by the syphilis bacterium. It is a flocculation test, meaning the lab mixes your serum with a fat-based antigen and looks for clumping. The strength of the clumping is quantified by diluting your blood in steps (1:2, 1:4, 1:8, and so on) until the reaction disappears. The last dilution that still clumps becomes your titer.
Because these antibodies are not specific to the syphilis bacterium itself, RPR is almost always paired with a treponemal test that directly detects antibodies to the organism. The treponemal test confirms exposure. The RPR tells you how active the infection is right now.
Higher RPR titers track with more active, infectious disease. Rapid tests linked to RPR perform well when the titer is 1:8 or higher, with sensitivity around 94 to 97 percent, but sensitivity drops sharply at titers of 1:4 or below. High titers generally signal primary, secondary, or early latent syphilis, while very low or nonreactive results can mean very early infection, late latent disease, or successfully treated infection.
A rising titer, defined as a fourfold or greater jump (such as 1:8 climbing to 1:32), suggests either a new infection, a reinfection, or treatment failure. A fourfold or greater fall after therapy (such as 1:32 dropping to 1:8) is the standard marker that treatment is working.
This is where RPR earns its keep. In one study of people treated for early syphilis, 88 percent achieved a fourfold decline by three months and about 78 percent showed an eightfold decline by six months, though only 17 percent became completely nonreactive by 12 months. In pregnancy, titers fall with a median half-life of roughly one month.
Not everyone normalizes. A systematic review found that roughly 12 percent show serologic non-response (less than a fourfold drop) and 35 to 44 percent remain serofast, meaning they stay positive at a low titer for years despite adequate treatment. A serofast state is not the same as treatment failure. It reflects residual antibodies from past infection, and in one study of HIV-negative patients with serologic non-response or lack of seroreversion, re-treatment did not meaningfully change outcomes in the short term.
Serum RPR of 1:32 or higher has been linked to increased risk of neurosyphilis, and normalization of serum RPR after treatment strongly predicts that cerebrospinal fluid abnormalities and clinical signs of neurosyphilis will also resolve. That means watching your RPR over time can help avoid repeat spinal taps.
One important caveat: ocular syphilis, which can cause permanent vision loss, sometimes occurs in people with nonreactive or very low RPR. In a retrospective study of patients with ocular syphilis, those with a nonreactive RPR looked clinically similar to those with low titers, and antibiotic treatment helped most of them. A low or negative RPR does not rule out serious syphilis when your eyes or nerves are involved.
RPR is fundamentally a reactive or nonreactive test. There is no classic normal range. If your blood reacts, the lab runs serial dilutions to produce a titer. Different labs can report different titers on the same blood sample, with variation of up to threefold documented between labs in one Ugandan screening study. Compare your results within the same lab over time for the most meaningful trend.
| Result | Typical Meaning |
|---|---|
| Nonreactive | No active syphilis antibody activity detected. In combination with a negative treponemal test, this is the reassuring result. |
| Reactive, titer 1:1 to 1:4 | Can indicate very early infection, late latent disease, successfully treated past infection, or a biologic false positive. Requires treponemal confirmation and clinical context. |
| Reactive, titer 1:8 or higher | Strongly associated with active, infectious syphilis, especially if paired with a positive treponemal test. Higher titers correlate with more active disease and higher neurosyphilis risk. |
| Fourfold rise from prior titer | Suggests new infection, reinfection, or treatment failure. |
| Fourfold fall after treatment | Standard marker of adequate therapeutic response. |
RPR titers can shift substantially on their own. In a mostly HIV-positive cohort, 27 percent of people had at least a twofold change and 10 percent had at least a fourfold change in the 1 to 3 months before treatment, without any therapy. In a separate 766-person study, about 15 percent of people had a fourfold rise or fall between their first presentation and the day treatment was given, with more change occurring the longer the gap between visits.
Even right after treatment, titers do not always behave. About 20 percent of people with early syphilis had at least a one-dilution rise in the two weeks after therapy. These post-treatment bumps rarely changed six-month outcomes, with only about 3 percent reclassified based on them. The practical takeaway: one number is a snapshot. A trajectory is the story.
If you are being treated for syphilis, the standard rhythm is to retest your RPR at 3, 6, and 12 months after therapy to confirm a fourfold decline. If you are at ongoing risk of exposure, annual testing is a floor, and every 3 months is reasonable if you fall into a higher-risk group. If your titer rises fourfold on any retest while you are not being actively treated, that signals reinfection and needs prompt evaluation.
Because titers can drift day to day, if a result between diagnosis and treatment looks different than expected, the lab should repeat the RPR on the day treatment is given. That repeat becomes your real baseline for judging future decline.
RPR can produce false positives in several situations. In large screening programs, only 36 to 37 percent of RPR-reactive samples were confirmed as syphilis by a treponemal test, meaning most reactive RPR results in low-risk people reflect something other than active infection.
One specific technical point: CSF RPR, used to evaluate neurosyphilis, is less sensitive than CSF VDRL and should not be substituted for it when a lumbar puncture is being done.
A reactive RPR is not a diagnosis on its own. The next step is always a treponemal confirmatory test (such as TPPA, FTA-ABS, or a treponemal immunoassay). The combination of reactive RPR plus positive treponemal test confirms syphilis exposure and points to active or recent infection if the titer is meaningful.
If both tests are positive, the decision pathway depends on your history, symptoms, and titer. You should be evaluated by a clinician experienced in sexually transmitted infections, who will stage the infection (primary, secondary, early latent, late latent, or tertiary) and check for neurological or eye involvement. Standard treatment is benzathine penicillin G. A single intramuscular dose of 2.4 million units treats early syphilis with a 90 to 100 percent success rate in systematic review data, and a randomized trial showed no added benefit from additional weekly doses for early syphilis in people with or without HIV.
If you have ongoing exposure risk, concurrent HIV testing, hepatitis testing, and screening for gonorrhea and chlamydia should be ordered alongside RPR. HIV co-infection can slow the rate at which your RPR falls after treatment and increases the chance of remaining serofast, so the interpretation of post-treatment titers must account for HIV status.
Evidence-backed interventions that affect your RPR Titer level
RPR Titer is best interpreted alongside these tests.